President and Chief Operating Officer
John Temperato joined Melinta Therapeutics in February 2016 as President and Chief Operating Officer, bringing with him over 23 years of broad-based commercial expertise in pharmaceutical, biotech, drug delivery/device products.
Prior to joining Melinta, Mr. Temperato held multiple leadership positions in sales and managed markets during his 11-year tenure at Salix Pharmaceuticals, where he most recently served as the Senior Vice President of Sales and Managed Markets. In this role, Mr. Temperato was a member of the Senior Staff Leadership Team that reported directly to the CEO and Board of Directors. Mr. Temperato played a critical role in the acquisition and in-licensing of multiple portfolio-expansion products, including the successful commercialization and growth of Xifaxan (a non-systemic antibiotic) for hepatic encephalopathy and irritable bowel syndrome (IBS-D). Mr. Temperato also played a principal role in the building, development, and management of seven specialized sales teams across multiple channels.
Before his role at Salix Pharmaceuticals, Mr. Temperato was a Business Unit Head at Celltech Pharmaceuticals, where he was responsible for the strategic development and execution of integrated payer and distribution marketing, which included contracting and reimbursement with various channels.
Mr. Temperato earned his Bachelor of Science degree in Marketing from the University of Bridgeport in Connecticut, and is a member of several distinguished healthcare organizations, including the Academy of Managed Care Pharmacy and National Business Group on Health.